Can Genetic Testing Predict Whether Caffeine Prevents Attention Lapses? A 37-Person Sleep-Loss Trial

Answer: Not reliably for an individual. In a randomized, blinded crossover experiment, 37 healthy adults completed repeated vigilance tests during prolonged wakefulness after caffeine or placebo. Certain variants in TNF, COMT, and PER3 were associated with differences in how caffeine-related vigilance effects appeared across testing periods. But the findings were small-group, task-dependent associations—not a clinically validated genetic test of stimulant response. The ADORA2A variant influenced the response to time awake without demonstrating a corresponding genotype-by-caffeine effect on vigilance lapses. No one was tested driving, and no caffeine concentration was quantified in forensic blood.

The original empirical source is Erblang and colleagues’ 2021 article, Genetic Determinants of Neurobehavioral Responses to Caffeine Administration during Sleep Deprivation: A Randomized, Cross Over Study (NCT03859882), published in Genes. The full primary Methods, Results, tables, figures, and Discussion—not an abstract or secondary summary—are the basis of this explanation. Read the original peer-reviewed trial (DOI: 10.3390/genes12040555).

What is the precise forensic-science question?

Fatigue and stimulant exposure can coexist. A witness, driver, shift worker, aircraft operator, or other individual may report taking caffeine to remain alert after lost sleep. Genetic testing might seem to promise a simple answer: identify a favorable variant and conclude that caffeine neutralized fatigue. This study does not permit that conclusion. It asks a narrower experimental question: whether four selected single-nucleotide polymorphisms modified group patterns of computerized psychomotor vigilance and subjective sleepiness under two controlled beverage conditions during sustained wakefulness.

The distinction matters because genetic susceptibility, administered dose, task performance, perceived alertness, electroencephalographic activity, and a measured drug concentration answer different questions. The presence of a DNA variant is not a quantitative measure of caffeine in blood; fewer group-average lapses are not proof of safe performance at an identified time. A laboratory result is only as probative as the actual variable measured and the uncertainty surrounding it.

How many people participated, and what was repeated?

The investigators enrolled 38 adults. One participant was excluded after significant nausea and vomiting following caffeine, leaving 37 independent participants for the main analysis: 21 women and 16 men, with a mean age reported as 33.5 years. The subjects were screened to exclude important medical, psychiatric, and sleep-related disorders. Habitual caffeine consumption averaged about 250 mg per day. They were not a representative sample of all adults, commercial drivers, or people with sleep apnea or a substance-use disorder.

Each participant underwent a placebo condition and a caffeine condition under a randomized, double-blind crossover design. Within a condition the participants repeatedly completed the same computerized assessments at set hours. Six test occasions, four oral administrations across two study days, and numerous reaction-time stimuli do not multiply the sample into dozens or hundreds of independent people. The independent human denominator remains 37 for the main behavioral study; individual genotype strata are smaller still.

The investigators deliberately prioritized certain genetic profiles when selecting the final twelve subjects. This helped achieve minimum subgroup numbers but also makes genotype frequencies less representative of an unscreened population. A result from a deliberately enriched research sample should not be converted into a population-wide prediction without external validation.

What caffeine dose was actually administered?

The active intervention was 2.5 mg of caffeine per kilogram of body weight, as powder mixed into a decaffeinated beverage; the matching placebo was a decaffeinated beverage designed to resemble it. The schedule gave a dose at approximately 8:30 a.m. and 2:30 p.m. on each of two testing days. Thus, the planned experimental exposure was two separate 2.5 mg/kg administrations per study day—not an undifferentiated 2.5 mg/kg for the entire observation period. A single universal milligram amount cannot be assigned to all participants because dosing was weight-based.

Participants were followed in a controlled laboratory through roughly 38 hours of continuous wakefulness. The principal computerized vigilance tests were scheduled at about 2, 8, 14, 20, 26, and 32 hours awake. Some tests therefore occurred after a recent caffeine administration and others after a longer interval. The schedule is essential when interpreting effects, because both sleep pressure and time since the last dose change over the protocol. The paper did not measure an individual’s actual internal caffeine concentration at these moments.

What did the investigators directly measure?

The key behavioral outcome was a ten-minute psychomotor vigilance task (PVT). A participant responded to an intermittent visual stimulus as quickly as possible. Responses exceeding 500 milliseconds were counted as lapses; a separate speed measure was derived from reaction time. The Karolinska Sleepiness Scale (KSS) recorded how sleepy participants said they felt on a one-to-nine scale. A 19-electrode scalp EEG recorded electrical activity while participants performed selected PVT sessions, with attention to theta and alpha frequencies.

The researchers also collected EDTA blood-cell specimens for DNA genotyping. They used loop-mediated isothermal amplification with melting-curve analysis to classify selected SNPs. That is a genuinely physical biological laboratory analysis, but its analyte is human genetic sequence—not caffeine, paraxanthine, another drug, or a quantitative protein biomarker of impairment. The published methods do not provide a validated caffeine assay, a caffeine blood concentration, a caffeine pharmacokinetic curve, or a cross-matrix conversion factor.

Which four genetic variants were studied?

The four variants were TNF rs1800629, ADORA2A rs5751876, PER3 rs228697, and COMT rs4680. They relate to different biological systems: inflammatory signaling, adenosine receptors, circadian regulation, and catecholamine metabolism. A genetic label is not a direct assay of circulating TNF-alpha protein, receptor occupancy, clock-gene expression, dopamine, or caffeine disposition.

When variants were uncommon, the researchers combined heterozygous and less-common homozygous categories to permit analysis. For the main sample, the published genotype counts were 24 TNF G/G versus 13 A-allele carriers; 14 ADORA2A C/C versus 23 T-allele carriers; 31 PER3 C/C versus 6 C/G; and 11 COMT G/G, 14 G/A, and 12 A/A. Those are four different partitions of the same 37 people, not four independent cohorts of 37. The six-member PER3 variant subgroup illustrates the considerable imprecision that can arise from small cells.

Did caffeine reduce vigilance lapses during sleep deprivation?

Yes, at the level of selected group contrasts. Lapses increased as wakefulness extended into the night and following day. Relative to placebo, the caffeine condition generally showed fewer lapses between about 14 and 32 hours awake. Response speed was higher in the caffeine condition at several specific testing times, including approximately 8, 26, and 32 hours awake. Those observations are compatible with caffeine mitigating some laboratory effects of fatigue.

But mitigation is not elimination. Sleep loss still imposed substantial strain on the experimental participants, and a lower average lapse count does not establish that no delayed responses occurred. The paper did not provide a validated PVT cutoff that translates directly into a legal driving-impairment threshold. Nor did it establish what a particular participant’s reaction time was during a real hazard. Even an apparently strong condition-level difference must be interpreted in relation to the tested endpoint and the underlying sampling uncertainty.

Did the TNF-alpha variant identify people who were protected?

No. For TNF rs1800629, the table reports a genotype-by-treatment effect on PVT lapses and a borderline three-way genotype-by-wakefulness-by-treatment comparison. The A-allele group showed significant caffeine-versus-placebo differences at several scheduled times, while G/G carriers showed them at fewer times. That difference in the pattern of significant post hoc contrasts cannot by itself establish that one genotype’s absolute performance was superior to the other genotype’s.

The investigators explicitly reported that genotype groups did not differ significantly in their PVT outcomes at individual test times in their post hoc comparisons. Their discussion suggests that apparent caffeine responsiveness in A-allele carriers may partly reflect worse untreated performance rather than exceptional protection. This is a central warning against presenting a genotype as a performance certificate. The original three-way p value printed at approximately .05 is especially sensitive to the convention used for statistical significance and does not justify a categorical personal prediction.

What did COMT predict, and when?

For COMT rs4680, the original table reports a three-way genotype-by-wakefulness-by-treatment interaction for PVT lapses (p = .04). A-allele carriers showed greater deterioration than G/G carriers in a selected placebo comparison after about 20 hours awake, with an apparent benefit from caffeine at that point. At later observations—approximately 26 and 32 hours—the authors did not demonstrate a stable genotype difference in lapse performance that would allow reliable ranking of individuals.

The authors did not identify a significant COMT main effect across all PVT lapses, response speed, and subjective sleepiness. Genotype interactions with waking duration and caffeine also were nonsignificant for PVT speed. The practical conclusion is that a context-dependent interaction was observed for one behavioral endpoint in a small sample, rather than a universal COMT rule for stimulant protection, safe operation, or caffeine dosing.

What did the PER3 variant add?

For PER3 rs228697, the main table reports genotype-by-treatment interactions for both lapse number and speed. In selected time-specific comparisons, caffeine was associated with fewer lapses in both C/C and C/G groups, although the precise times differed. A significant speed advantage at approximately 26 hours was reported in C/C carriers, not in the six-person C/G group. The observed pattern may justify replication, but an apparent difference in a small subgroup’s p value does not establish a reliable biological difference in treatment efficacy.

The paper did not show a significant PER3 genotype-by-wakefulness interaction for PVT speed; the relevant value was p = .82. Nor did PER3 produce a significant genotype-by-treatment effect on self-reported KSS sleepiness in Table 2. A near-threshold three-way KSS result was p = .06 and remains statistically nonsignificant at a conventional .05 threshold. This is a useful example of how the direction of a plotted curve, a treatment contrast, and an interaction test can convey different levels of evidence.

Why does ADORA2A matter if it did not predict caffeine benefit?

ADORA2A rs5751876 influences the adenosine-related biology frequently discussed in connection with caffeine. In this experiment, the genotype-by-time-awake interaction for PVT lapses was reported at p = .02, and T-allele carriers had more lapses than C/C carriers in a selected comparison at approximately 32 hours. Yet the genotype-by-caffeine-treatment interaction for lapses was nonsignificant (p = .45), as was the three-way interaction (p = .47). Neither PVT speed nor subjective sleepiness supplied the missing predictive treatment effect.

The investigators also observed different reported customary caffeine intakes across these genotype groups. That introduces a plausible behavioral or physiological confounder: habitual consumption, tolerance, sleep history, and genotype are not randomly assigned together. An observed genotype association with worsening during deprivation is not equivalent to proof that the genotype determines caffeine effectiveness. This article distinguishes those two questions because conflating them would overstate what was randomized.

Two evidence tables: subgroup counts and actual interaction tests

These tables reorganize values reported in the original article for critical interpretation. A reported p value reflects a specified test, not a medical or legal diagnostic threshold. The analysis did not estimate how accurately any genetic profile would classify real-world workers as fit or unfit.

NS means not statistically significant under the comparison reported in the source. Exact model degrees of freedom and additional original tests are available in its Table 2. The table does not supply sensitivity, specificity, or a cross-validated risk score for anyone’s fitness to drive.

What about reported sleepiness rather than measured response speed?

KSS is a subjective report on a nine-point sleepiness scale. Across the experiment, sleepiness generally increased as wakefulness continued. The source described general treatment effects in its overall models, but it found no significant time-specific caffeine-versus-placebo KSS differences in Figure 2. For the four genetic variants, the main genotype-specific caffeine interaction tests on KSS were nonsignificant in its tabulated analysis. The different levels of analysis should not be represented as a contradiction resolved in favor of one particular person’s perceived alertness.

These null findings make it inappropriate to say that any tested genotype guaranteed subjective wakefulness with caffeine. They also demonstrate why a person who reports feeling alert might nonetheless have delayed responses. Self-rating, laboratory reaction-time distributions, and real-world task reliability are related but noninterchangeable evidence categories. The study did not establish a legally meaningful correspondence between a KSS score and an actual traffic hazard.

Did the EEG prove that caffeine restored normal brain activity?

No. An EEG records electrical potentials at scalp electrodes and derives frequency-band estimates; it does not measure caffeine molecules or neural adenosine-receptor occupancy. The researchers examined theta and alpha power during selected PVT sessions at roughly 2 and 26 hours awake. Six participants were omitted from EEG analysis because signal quality was insufficient, leaving 31 for that component. Thus the EEG denominator differs from the 37-person principal behavioral analysis.

In the paper, some genotype categories showed higher theta activity during sleep deprivation, particularly under placebo, and centrotemporal theta measures were positively correlated with lapse counts. But the authors also reported several nonsignificant interactions and post hoc contrasts for the EEG theta-to-alpha ratio. Correlation between electrical activity and delayed computerized responses within a selected small sample is not a clinically validated diagnostic index of fatigue, an exposure-time assay, or a predictor of an individual’s future accident.

One might propose a multi-marker classifier combining genotype, habitual caffeine intake, PVT, and EEG. The present experiment did not develop and independently validate such a classifier. It offers preliminary evidence for particular interactions to investigate, not a preapproved system for assigning risk to workers or judging the credibility of a fatigued witness.

Does a blood-derived DNA result tell us blood caffeine concentration?

It does not. In this original study, blood-cell material collected in EDTA tubes was used for genetic analysis, not for a reported quantitative caffeine determination. The blood specimen’s presence in the methods section therefore must not be turned into a claim that venous whole-blood caffeine concentrations were measured. There was no report of sample-matched caffeine or paraxanthine concentrations expressed in ng/mL, a validated chromatographic drug assay, calibration range, limit of detection or quantitation, or measured clearance curve.

A DNA polymorphism is a relatively stable personal trait. Oral caffeine intake is an event-specific exposure, and the circulating concentration can depend on dose, absorption, distribution, metabolism, time, and circumstances. A genotype may motivate a pharmacological hypothesis, but it is not an interchangeable substitute for a contemporaneous analyte measurement. Even directly measured venous whole-blood caffeine would require matrix-specific context and could not automatically establish a person’s reaction-time distribution at a legally relevant instant.

For the broader evidentiary framework, see the published same-domain guides on why biological matrices cannot be interchanged, what chemical confirmatory testing actually establishes, and why a timed drug level differs from a dose history. Those guides provide context; they are not extra sources of the original genotype experiment’s numerical results.

Why is the genetic finding not ready for individual forensic classification?

Several limitations operate together. Only 37 volunteers entered the primary analysis, genotype groups sometimes contained just six people, and the final recruitment deliberately balanced selected variants. The investigators tested four polymorphisms across multiple behavioral and physiological outcomes and several waking intervals. Some original interaction probabilities were near conventional significance thresholds. An isolated nominally significant result is not the same thing as a replicated, calibrated prediction model with a known false-positive rate in the population to which a particular legal question relates.

The conditions were unusually controlled: fixed light and room temperature, supervised wakefulness, standardized meals, no alcohol or other psychoactive substances, and scheduled computer tests. That control strengthens interpretation of the randomized caffeine-versus-placebo comparison; it does not randomize people’s inherited genotype, habitual intake, occupation, physiology, or past sleep exposure. Study participants were screened against several common disorders and therefore do not stand in for every person whose sleep history is contested.

The paper’s statistical tables also require care. Some printed F statistics and their associated p values appear internally difficult to reconcile, and the authors aggregate rare genotypes for some analyses. The prudent approach is to report the original numeric result as printed, identify the comparison and uncertainty, and avoid manufacturing revised coefficients, sensitivity estimates, or a threshold that was never validated. Post hoc time-point differences should not be silently promoted into general individual causation.

What does the experiment say about accident reconstruction or witness reliability?

It establishes no case-specific event cause. No subject drove a vehicle on a public road, encountered an actual unexpected pedestrian hazard, testified as an eyewitness under forensic conditions, or experienced a documented collision as an outcome. The PVT is a useful standardized sustained-attention task; it is not itself a reconstructed road event. A real incident analysis would require the person’s relevant sleep opportunity, timeline, potentially measured chemicals, clinical background, task demands, observations, and appropriate alternative explanations.

It would be equally incorrect to infer that a person with a variant associated with fewer caffeine-placebo lapses must have been safe, or that a variant with a more adverse placebo performance pattern caused negligent behavior. Many influences on performance were not measured at an individual incident time. Even the source investigators noted a need for larger and more varied studies. Genetic data should not be given an evidentiary weight that exceeds a 37-person experimental interaction.

What is the narrow defensible conclusion?

The source supports a restricted but useful scientific statement: caffeine reduced selected laboratory vigilance deficits during controlled prolonged wakefulness, and the pattern of certain caffeine-associated PVT outcomes depended in part on small genotype strata. TNF, COMT, and PER3 displayed selected interaction results; ADORA2A related to deterioration with time awake without a significant corresponding genotype-by-treatment lapse interaction. Many genotype and outcome contrasts were genuinely nonsignificant.

It does not establish a reliable personal genotype-based caffeine prescription, restoration of safe operation, an objective forensic fatigue threshold, a blood caffeine concentration, or an individual accident cause. The most useful expert distinction is between an experimental group interaction and a validated individual decision rule. The paper contributes to the former, not the latter.

Frequently asked questions

1. Can a TNF-alpha SNP tell an expert that caffeine made a particular driver safe?

No. The trial reported a genotype-associated pattern of caffeine versus placebo PVT differences in healthy sleep-deprived volunteers. Its TNF three-way result was printed near p = .05, and genotype differences in individual test-time outcomes were not robustly demonstrated. It neither evaluated actual driving nor validated a driver-specific cutoff. A DNA result cannot reconstruct someone’s hazard response or establish safety.

2. Did COMT predict that everyone with an A allele performed better on caffeine?

No. A COMT interaction was reported for lapses across treatment and wakefulness, but the main genotype effect was not generally significant and the selected early-night contrast did not persist as a simple genotype ranking at later periods. Treatment-related improvement in a subgroup does not prove superior absolute performance or an individual benefit at an unobserved time.

3. What was the strongest ADORA2A result?

The original PVT lapse genotype-by-time-awake interaction was p = .02, reflecting differential deterioration with continued wakefulness. Crucially, the genotype-by-caffeine interaction was p = .45 and the three-way interaction was p = .47. It is not accurate to convert the time-awake association into proof that ADORA2A predicted caffeine response.

4. Why did the EEG analysis have fewer participants than the PVT analysis?

Thirty-seven healthy adults remained in the principal experiment, but poor-quality scalp EEG recordings led to six EEG exclusions. The EEG analysis therefore used 31 participants. Electrical epochs and electrodes are repeated measurements within people, not extra independent participants. EEG theta is a physiological proxy and not a quantitative caffeine blood assay.

5. Was caffeine tested in venous whole blood, serum, plasma, urine or oral fluid?

Not quantitatively in this publication. Researchers collected EDTA blood cells for DNA SNP testing, which must not be confused with chemical identification or quantitation of caffeine in forensic venous whole blood. The study did not report measured caffeine or paraxanthine in blood, plasma, serum, urine, oral fluid, or hair. The 2.5 mg/kg value was an administered oral dose.

6. Did caffeine also make participants feel significantly less sleepy at each test time?

Not consistently. The overall modeling described caffeine-related effects, but the plotted KSS time-specific caffeine-versus-placebo comparisons were not significant, and the genotype-by-treatment KSS results were nonsignificant in the main genetic interaction table. A participant can report a particular level of sleepiness while still producing very slow responses to a visual stimulus.

7. What primary citation should accompany a professional explanation?

Erblang M, Sauvet F, Drogou C, Quiquempoix M, Van Beers P, Guillard M, Rabat A, Trignol A, Bourrilhon C, Erkel M-C, Léger D, Thomas C, Gomez-Merino D, Chennaoui M. Genetic Determinants of Neurobehavioral Responses to Caffeine Administration during Sleep Deprivation: A Randomized, Cross Over Study (NCT03859882). Genes 2021;12:555. Original primary study DOI: 10.3390/genes12040555. Its complete Methods, source Tables 1–2, Figures 2–5, Discussion, and printed statistical tests should control any expert use of the result.